Daewoong Pharmaceutical Overview

  • Year Founded
  • 1945

Year Founded

  • Status
  • Public

  • Employees
  • 1,777

Employees

  • Stock Symbol
  • 069620

Stock Symbol

  • Investments
  • 41

  • Share Price
  • $76.36
  • (As of Friday Closing)

Daewoong Pharmaceutical General Information

Description

Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Contact Information

Formerly Known As
Daehan Vitamin Industries, Joseon Ganyu Pharmaceutical Company
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Bongeunsa-ro 114-gil 12
  • Seoul, Gangnam
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • Bongeunsa-ro 114-gil 12
  • Seoul, Gangnam
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Daewoong Pharmaceutical Stock Performance

As of 13-Nov-2026, Daewoong Pharmaceutical’s stock price is $76.36. Its current market cap is $879M with 11.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$76.36 $76.68 $67.87 - $137.07 $879M 11.5M 20.2K $11.71

Daewoong Pharmaceutical Financials Summary

As of 30-Jun-2026, Daewoong Pharmaceutical has a trailing 12-month revenue of $1.13B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,398,160 1,871,731 1,404,004 1,338,644
Revenue 1,126,759 1,103,823 1,042,689 1,051,917
EBITDA 178,001 177,625 78,730 134,842
Net Income 134,692 137,622 18,128 93,112
Total Assets 1,644,560 1,640,822 1,342,170 1,373,740
Total Debt 599,489 575,962 440,775 342,420
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Daewoong Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Daewoong Pharmaceutical‘s full profile, request access.

Request a free trial

Daewoong Pharmaceutical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfo
Drug Discovery
Seoul, South Korea
1,777 As of 2025

Indianapolis, IN
 

Karachi, Pakistan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Daewoong Pharmaceutical Competitors (8)

One of Daewoong Pharmaceutical’s 8 competitors is Lilly USA, a Corporation company based in Indianapolis, IN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lilly USA Corporation Indianapolis, IN
Hoechst Pakistan Corporate Backed or Acquired Karachi, Pakistan
Celltrion Formerly VC-backed Incheon, South Korea
GSK Corporation London, United Kingdom
Dr. Reddy's Corporation Hyderabad, India
You’re viewing 5 of 8 competitors. Get the full list »

Daewoong Pharmaceutical Patents

Daewoong Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026235345-A1 Pharmaceutical composition for preventing or treating metabolic dysfunction-associated steatotic liver disease, comprising enavogliflozin as active ingredient Pending 08-May-2025
WO-2026230955-A1 Pharmaceutical composition for preventing or treating hydrocephalus or ventriculomegaly due to periventricular ciliary dysfunction comprising enavogliflozin Pending 30-Apr-2025
WO-2026225879-A1 Pharmaceutical composition for preventing or treating cancer or tumors Pending 25-Apr-2025
WO-2026221464-A1 Sustained release pharmaceutical formulation comprising ropivacaine and preparation method thereof Pending 17-Apr-2025
WO-2026216985-A1 Crystalline form of 2'-chloro-n-(6-(cyclopropylethynyl)thiazolo[4,5-b]pyrazin-2-yl)-5'-methoxy-6-methyl-4,4'-bipyridine-3-carboxamide Pending 10-Apr-2025
To view Daewoong Pharmaceutical’s complete patent history, request access »

Daewoong Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Daewoong Pharmaceutical Investments & Acquisitions (41)

Daewoong Pharmaceutical’s most recent deal was a Early Stage VC with Hurotics for . The deal was made on 15-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hurotics 15-Oct-2026 Early Stage VC Therapeutic Devices
Puzzle AI 27-Aug-2026 Later Stage VC Medical Records Systems
EXOSYSTEMS 28-Jun-2026 Later Stage VC Diagnostic Equipment
PROMEDIUS 05-Jun-2026 Later Stage VC Decision/Risk Analysis
Turn Biotechnologies 21-May-2026 Merger/Acquisition Drug Discovery
You’re viewing 5 of 41 investments and acquisitions. Get the full list »

Daewoong Pharmaceutical ESG

Risk Overview

Risk Rating

Updated November, 05, 2026

29.77 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Daewoong Pharmaceutical’s complete esg history, request access »

Daewoong Pharmaceutical Exits (6)

Daewoong Pharmaceutical’s most recent exit was on 29-Jul-2022 from AEON Biopharma. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
AEON Biopharma 29-Jul-2022 Completed
  • 2 buyers
Seers (Monitoring Equipment) 14-May-2022 Completed
  • 8 buyers
Oncocross 01-Mar-2021 Completed
  • 4 buyers
Inventage Lab 01-Jan-2020 Completed
  • 17 buyers
Parataxis Korea 01-Apr-2019 Later Stage VC Completed
  • 11 buyers
You’re viewing 5 of 6 exits. Get the full list »

Daewoong Pharmaceutical Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Daewoong Investment Seoul, South Korea 2023
CGBio Seoul, South Korea 2006
Liaoning Daewoong Pharmaceutical Benxi, China

Daewoong Pharmaceutical FAQs

  • When was Daewoong Pharmaceutical founded?

    Daewoong Pharmaceutical was founded in 1945.

  • Where is Daewoong Pharmaceutical headquartered?

    Daewoong Pharmaceutical is headquartered in Seoul, South Korea.

  • What is the size of Daewoong Pharmaceutical?

    Daewoong Pharmaceutical has 1,777 total employees.

  • What industry is Daewoong Pharmaceutical in?

    Daewoong Pharmaceutical’s primary industry is Drug Discovery.

  • Is Daewoong Pharmaceutical a private or public company?

    Daewoong Pharmaceutical is a Public company.

  • What is Daewoong Pharmaceutical’s stock symbol?

    The ticker symbol for Daewoong Pharmaceutical is 069620.

  • What is the current stock price of Daewoong Pharmaceutical?

    As of 13-Nov-2026 the stock price of Daewoong Pharmaceutical is $76.36.

  • What is the current market cap of Daewoong Pharmaceutical?

    The current market capitalization of Daewoong Pharmaceutical is $879M.

  • What is Daewoong Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Daewoong Pharmaceutical is $1.13B.

  • Who are Daewoong Pharmaceutical’s competitors?

    Lilly USA, Hoechst Pakistan, Celltrion, GSK, and Dr. Reddy's are some of the 8 competitors of Daewoong Pharmaceutical.

  • What is Daewoong Pharmaceutical’s annual earnings per share (EPS)?

    Daewoong Pharmaceutical’s EPS for 12 months was $11.71.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process